In 1993, Napoleone Ferrara’s group demonstrated that treatment with an anti-VEGF monoclonal antibody decreases vascular density and inhibits tumor growth in nude mice bearing xenografts of rhabdomyosarcoma, glioblastoma multiforme, and leiomyosarcoma (Kim et al., 1993). Here, VEGFA is linked to neoplasm.